Drugging the p53 pathway: understanding the route to clinical efficacy

Cyclotherapy: opening a therapeutic window in cancer treatment

(2015) Ingeborg M.M. van Leeuwen   Oncotarget

Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation

(2014) Ramiro París et al.   CELL CYCLE

In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition

(2014) Siau Jia Wei et al.   PLoS One

Discovery of a new small-molecule inhibitor of p53–MDM2 interaction using a yeast-based approach

(2013) Mariana Leão et al.   BIOCHEMICAL PHARMACOLOGY

Affinity-based screening of MDM2/MDMX–p53 interaction inhibitors by chemical array: Identification of novel peptidic inhibitors

(2013) Taro Noguchi et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

(2013) K. Kojima et al.   BLOOD

Restoring p53 Function in Human Melanoma Cells by Inhibiting MDM2 and Cyclin B1/CDK1-Phosphorylated Nuclear iASPP

(2013) Min Lu et al.   CANCER CELL

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

(2013) C. Tovar et al.   CANCER RESEARCH

Cisplatin Hypersensitivity of Testicular Germ Cell Tumors Is Determined by High Constitutive Noxa Levels Mediated by Oct-4

(2013) M. Gutekunst et al.   CANCER RESEARCH

Non-Cell-Autonomous Tumor Suppression by p53

(2013) Amaia Lujambio et al.   CELL

On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: A Brownian dynamics study

(2013) Karim ElSawy et al.   CELL CYCLE

Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest

(2013) Changyou Li et al.   CELL CYCLE

A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis

(2013) M Kracikova et al.   CELL DEATH AND DIFFERENTIATION

Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors

(2013) Felix Gonzalez-Lopez de Turiso et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthesis, in Vitro, and in Cell Studies of a New Series of [Indoline-3,2′-thiazolidine]-Based p53 Modulators

(2013) Alessia Bertamino et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

(2013) Qingjie Ding et al.   JOURNAL OF MEDICINAL CHEMISTRY

A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice

(2013) Yujun Zhao et al.   JOURNAL OF MEDICINAL CHEMISTRY

In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide

(2013) Yanbin Ji et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Small molecule induced reactivation of mutant p53 in cancer cells

(2013) Xiangrui Liu et al.   NUCLEIC ACIDS RESEARCH

Inhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides

(2013) Siau Jia Wei et al.   PLoS One

Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET

(2013) R. Shalom-Feuerstein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

APR-246/PRIMA-1MET rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations

(2013) J. Shen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

(2013) Yong S. Chang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy

(2013) K. Shchors et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry

(2013) Lenka Hernychova et al.   PROTEOMICS

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

(2013) D. M. Molina et al.   SCIENCE

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

(2013) Binh Vu et al.   ACS Medicinal Chemistry Letters

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

(2013) Christopher D. Wassman et al.   Nature Communications

p53 DNA Binding Cooperativity Is Essential for Apoptosis and Tumor Suppression In Vivo

(2013) Oleg Timofeev et al.   Cell Reports

p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa

(2013) Liz J. Valente et al.   Cell Reports

Stabilizing the Pro-Apoptotic BimBH3 Helix (BimSAHB) Does Not Necessarily Enhance Affinity or Biological Activity

(2012) Toru Okamoto et al.   ACS Chemical Biology

Stapled Peptides with Improved Potency and Specificity That Activate p53

(2012) Christopher J. Brown et al.   ACS Chemical Biology

Structural insights into the dual-targeting mechanism of Nutlin-3

(2012) Jae-Sun Shin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia

(2012) M. S. Davids et al.   BLOOD

Correlation ofTP53andMDM2genotypes with response to therapy in sarcoma

(2012) Hege O. Ohnstad et al.   CANCER

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib

(2012) Ling Li et al.   CANCER CELL

ATM Phosphorylation of Mdm2 Ser394 Regulates the Amplitude and Duration of the DNA Damage Response in Mice

(2012) Hugh S. Gannon et al.   CANCER CELL

Allele-Specific p53 Mutant Reactivation

(2012) Xin Yu et al.   CANCER CELL

p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast Cancer

(2012) James G. Jackson et al.   CANCER CELL

Novel DNA Damage Checkpoints Mediating Cell Death Induced by the NEDD8-Activating Enzyme Inhibitor MLN4924

(2012) J. L. Blank et al.   CANCER RESEARCH

Small molecules that bind the Mdm2 RING stabilize and activate p53

(2012) P. Roxburgh et al.   CARCINOGENESIS

Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence

(2012) Tongyuan Li et al.   CELL

Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML

(2012) Thanh-Trang Vo et al.   CELL

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells

(2012) Ingeborg M.M. van Leeuwen et al.   CELL CYCLE

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX

(2012) Ryan E Henry et al.   EMBO JOURNAL

Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils

(2012) Alexander H Stegh   EXPERT OPINION ON THERAPEUTIC TARGETS

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status

(2012) G. Zauli et al.   HAEMATOLOGICA

Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy

(2012) Refik Kayali et al.   HUMAN MOLECULAR GENETICS

Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance inTP53wild-type ovarian cancer cells

(2012) Roser Mir et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction

(2012) Yosup Rew et al.   JOURNAL OF MEDICINAL CHEMISTRY

An Expeditious Synthesis of the MDM2–p53 Inhibitor AM-8553

(2012) Brian S. Lucas et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors

(2012) Klaus Michelsen et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Halogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53

(2012) Rainer Wilcken et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

(2012) R. J. Jones et al.   MOLECULAR CANCER THERAPEUTICS

Association of themiR-146aC>G,miR-149T>C,miR-196a2T>C, andmiR-499A>G polymorphisms with gastric cancer risk and survival in the korean population

(2012) Dae Ho Ahn et al.   MOLECULAR CARCINOGENESIS

ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53

(2012) Kelly D Sullivan et al.   Nature Chemical Biology

MDM4 is a key therapeutic target in cutaneous melanoma

(2012) Agnieszka Gembarska et al.   NATURE MEDICINE

Siladenoserinols A–L: New Sulfonated Serinol Derivatives from a Tunicate as Inhibitors of p53–Hdm2 Interaction

(2012) Yuichi Nakamura et al.   ORGANIC LETTERS

Improved eIF4E Binding Peptides by Phage Display Guided Design: Plasticity of Interacting Surfaces Yield Collective Effects

(2012) Weizhuang Zhou et al.   PLoS One

A Spiroligomer α-Helix Mimic That Binds HDM2, Penetrates Human Cells and Stabilizes HDM2 in Cell Culture

(2012) Zachary Z. Brown et al.   PLoS One

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

(2012) B. Graves et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B

(2012) R W Rooswinkel et al.   Cell Death & Disease

Inability of p53-reactivating compounds Nutlin-3 and RITA to overcome p53 resistance in tumor cells deficient in p53Ser46 phosphorylation

(2011) Teng Ma et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation

(2011) Jane M Valentine et al.   BMC CANCER

Translational approaches targeting the p53 pathway for anti-cancer therapy

(2011) Frank Essmann et al.   BRITISH JOURNAL OF PHARMACOLOGY

Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression

(2011) Colleen A. Brady et al.   CELL

BH3 activation blocks Hdmx suppression of apoptosis and cooperates with Nutlin to induce cell death

(2011) Mark Wade et al.   CELL CYCLE

NPMc+ AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds

(2011) Qiao Jing Lew et al.   CELL CYCLE

Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs

(2011) Rosa Puca et al.   CELL CYCLE

Mechanism-specific signatures for small-molecule p53 activators

(2011) Ingeborg M.M. van Leeuwen et al.   CELL CYCLE

Understanding Small-Molecule Binding to MDM2: Insights into Structural Effects of Isoindolinone Inhibitors from NMR Spectroscopy

(2011) Christiane Riedinger et al.   Chemical Biology & Drug Design

iASPP and Chemoresistance in Ovarian Cancers: Effects on Paclitaxel-Mediated Mitotic Catastrophe

(2011) L. Jiang et al.   CLINICAL CANCER RESEARCH

PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53

(2011) R. Zandi et al.   CLINICAL CANCER RESEARCH

Validation of MdmX as a therapeutic target for reactivating p53 in tumors

(2011) D. Garcia et al.   GENES & DEVELOPMENT

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein−Protein Interaction: Structure−Activity Studies Leading to Improved Potency

(2011) Ian R. Hardcastle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Identification of Two Reactive Cysteine Residues in the Tumor Suppressor Protein p53 Using Top-Down FTICR Mass Spectrometry

(2011) Jenna Scotcher et al.   JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex

(2011) M Konopleva et al.   LEUKEMIA

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia

(2011) E McCormack et al.   LEUKEMIA

MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer

(2011) Christian Tovar et al.   Molecular Cancer

Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells

(2011) Marc J. Rigatti et al.   MOLECULAR CARCINOGENESIS

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3

(2011) M H Aziz et al.   ONCOGENE

p53 Hypersensitivity Is the Predominant Mechanism of the Unique Responsiveness of Testicular Germ Cell Tumor (TGCT) Cells to Cisplatin

(2011) Matthias Gutekunst et al.   PLoS One

C-Terminal Substitution of MDM2 Interacting Peptides Modulates Binding Affinity by Distinctive Mechanisms

(2011) Christopher J. Brown et al.   PLoS One

Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages

(2011) D. Jiang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo

(2011) L. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

(2011) T. N. Chonghaile et al.   SCIENCE

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

(2011) M Michaelis et al.   Cell Death & Disease

Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis

(2010) Isabelle Sermet-Gaudelus et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Robust Generation of Lead Compounds for Protein-Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists

(2010) Anna Czarna et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim

(2010) L. Happo et al.   BLOOD

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

(2010) D. Yecies et al.   BLOOD

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

(2010) J. Long et al.   BLOOD

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma

(2010) Manujendra N. Saha et al.   CANCER BIOLOGY & THERAPY

A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53

(2010) Federico Bernal et al.   CANCER CELL

Blockade of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase and Murine Double Minute Synergistically Induces Apoptosis in Acute Myeloid Leukemia via BH3-Only Proteins Puma and Bim

(2010) W. Zhang et al.   CANCER RESEARCH

Specific activation of the p53 pathway by low dose actinomycin D: A new route to p53 based cyclotherapy

(2010) Meng Ling Choong et al.   CELL CYCLE

Life or death

(2010) Katharina Schlereth et al.   CELL CYCLE

Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53

(2010) C F Cheok et al.   CELL DEATH AND DIFFERENTIATION

Toward the Rational Design of p53-Stabilizing Drugs: Probing the Surface of the Oncogenic Y220C Mutant

(2010) Nicolas Basse et al.   CHEMISTRY & BIOLOGY

Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway

(2010) G. Zauli et al.   CLINICAL CANCER RESEARCH

Regulation of the p53 pathway by ubiquitin and related proteins

(2010) Andreas Hock et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Identification and Characterization of the First Small Molecule Inhibitor of MDMX

(2010) Damon Reed et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions

(2010) Chong Li et al.   JOURNAL OF MOLECULAR BIOLOGY

The missing Zinc: p53 misfolding and cancer

(2010) Stewart N. Loh   Metallomics

Targeted Quantitation of Site-Specific Cysteine Oxidation in Endogenous Proteins Using a Differential Alkylation and Multiple Reaction Monitoring Mass Spectrometry Approach

(2010) Jason M. Held et al.   MOLECULAR & CELLULAR PROTEOMICS

1,25-Dihydroxyvitamin D3 Enhances the Apoptotic Activity of MDM2 Antagonist Nutlin-3a in Acute Myeloid Leukemia Cells Expressing Wild-type p53

(2010) T. Thompson et al.   MOLECULAR CANCER THERAPEUTICS

DNA Binding Cooperativity of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis

(2010) Katharina Schlereth et al.   MOLECULAR CELL

Translating p53 into the clinic

(2010) Chit Fang Cheok et al.   Nature Reviews Clinical Oncology

Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides

(2010) Célia Floquet et al.   NUCLEIC ACIDS RESEARCH

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy

(2010) A S Azmi et al.   ONCOGENE

PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73

(2010) N Rökaeus et al.   ONCOGENE

Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells

(2010) R Puca et al.   ONCOGENE

D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms

(2010) M. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124

(2010) D. S. Auld et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding

(2010) Joel L. Kaar et al.   PROTEIN SCIENCE

DNA damage response to the Mdm2 inhibitor Nutlin-3

(2009) Rajeev Verma et al.   BIOCHEMICAL PHARMACOLOGY

Pharmaceuticals Targeting Nonsense Mutations in Genetic Diseases

(2009) Steven M. Rowe et al.   BIODRUGS

Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML

(2009) B. Z. Carter et al.   BLOOD

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Reversal of P-glycoprotein-Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3

(2009) M. Michaelis et al.   CANCER RESEARCH

Modes of p53 Regulation

(2009) Jan-Philipp Kruse et al.   CELL

MDM2 Antagonist Nutlin-3 Displays Antiproliferative and Proapoptotic Activity in Mantle Cell Lymphoma

(2009) Y. Tabe et al.   CLINICAL CANCER RESEARCH

Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMX

(2009) Jason Phan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2−Tumor Protein 53 Protein−Protein Interaction

(2009) John G. Allen et al.   JOURNAL OF MEDICINAL CHEMISTRY

Adaptive Evolution of p53 Thermodynamic Stability

(2009) Kian Hoe Khoo et al.   JOURNAL OF MOLECULAR BIOLOGY

Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53

(2009) Tom Van Maerken et al.   JNCI-Journal of the National Cancer Institute

Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?

(2009) Mark Wade et al.   MOLECULAR CANCER RESEARCH

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy

(2009) Colin J D Ross et al.   NATURE GENETICS

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

(2009) S. Sur et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression

(2009) D. S. Auld et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

(2009) M. Pazgier et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Biology of the Tumor Suppressor p53

(2008) Andreas C. Joerger et al.   Annual Review of Biochemistry

Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia

(2008) K. Kojima et al.   BLOOD

Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator

(2008) Sonia Lain et al.   CANCER CELL

In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute

(2008) E M Michalak et al.   CELL DEATH AND DIFFERENTIATION

Multiple Peptide Conformations Give Rise to Similar Binding Affinities: Molecular Simulations of p53-MDM2

(2008) Shubhra Ghosh Dastidar et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial

(2008) Eitan Kerem et al.   LANCET

Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2

(2008) J. Kitagaki et al.   MOLECULAR CANCER THERAPEUTICS

Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53

(2008) S. Supiot et al.   MOLECULAR CANCER THERAPEUTICS

Modelling Myc inhibition as a cancer therapy

(2008) Laura Soucek et al.   NATURE

Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA

(2008) Dmitry B. Veprintsev et al.   NUCLEIC ACIDS RESEARCH

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

(2008) F. M. Boeckler et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Introducing sense into nonsense in treatments of human genetic diseases

(2008) Liat Linde et al.   TRENDS IN GENETICS